Skip to main content
Toggle navigation
Login
Home
Back
Favorite
1
Like
Facebook
Tweet
Session II: Practical considerations, standard of care and emerging biomarkers
Debate: Cisplatin Ineligible Patient Underwent Radical Cystectomy with pT3N1 Bladder Urothelial Carcinoma with Extensive Squamous Cell Features. Adjuvant Nivolumab? Yes or No - YES
Wednesday, September 28, 2022
1:35 PM – 1:42 PM
Debate Speaker(s)
Matt Galsky, MD
Icahn School of Medicine at Mount Sinai